Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor

Agnieszka Pampuch; Chiara Cerletti; Giovanni de Gaetano

doi:10.1160/TH06-09-0491

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 96(06): 767-773
DOI: 10.1160/TH06-09-0491

Platelets and Blood Cells

Schattauer GmbH

Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y₁₂ receptor

Agnieszka Pampuch

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Chiara Cerletti

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Giovanni de Gaetano

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

› Institutsangaben

Abstract

Summary

There is need to improve platelet function testing to monitor the response to antiplatelet drugs. We compared flow-cytometric analysis of intraplatelet vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) to light-transmission aggregometry for the detection of drug-induced in-vitro inhibition of the platelet P2Y₁₂ ADP receptor on 22 healthy subjects (10 males, 12 females, 28.5 ± 6.6 years). The platelet reactivity index (PRI) of VASP was calculated both from mean fluorescence intensity (MFI) and percent of fluorescence-positive platelets in the presence of PGE₁ with or without ADP (10 µM). Platelet aggregation was induced by ADP (1.25, 2.5 and 5 µM). Cangrelor, a competitive inhibitor of the P2Y₁₂ receptor, preincubated 5 minutes, induced a concentration-dependent inhibition of platelet ADP-receptor function in both tests. Indeed PRI (%) based on either MFI or percent platelets gated were highly correlated with each other (r = 0.97, p<0.0001) and with aggregation in- duced by ADP. The IC₅₀ of cangrelor against each of the three ADP concentrations used in aggregometry increased from 5.8 ± 3.4 nM to 23.1 ± 4.0 nM and to 98 ± 25 nM, respectively. The IC₅₀ of cangrelor based on VASP-P was within the same range (25.5 ± 7.7 nM). No correlation was observed between IC₅₀ values of cangrelor and ADP concentrations giving 50% effect (EC₅₀) in the absence of the drug. However, at 10 nM cangrelor seven subjects could be identified by the VASP-P assay as “low responders” to the drug (PRI> 50%), and six of them also had an aggregation response to 5 µM ADP > 50%. These six subjects showed the lowest ADP EC₅₀ values in the absence of the drug, possibly reflecting high sensitivity of their platelet P2Y₁₂ receptors to ADP. In conclusion, both the VASP-P assay and light-transmission aggregometry detect in a comparable way in-vitro pharmacological inhibition of the platelet P2Y₁₂ ADP receptor and its individual variability.

Keywords

VASP phosphorylation - platelet aggregation - P2Y₁₂ ADP receptor antagonist - cangrelor

Volltext

Referenzen

References
1 Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e489-e493.
2 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-95.
3 Cattaneo M. Aspirin and clopidogrel : efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
4 Jaremo P, Lindahl TL, Fransson SG. et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-8.
5 de Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests?. J Thromb Haemost 2003; 09: 2048-50.
6 Geiger J, Teichmann L, Grossman R. et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957-65.
7 Schwarz UR, Geiger J, Walter U. et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Thromb Haemost 1999; 82: 1145-52.
8 Aleil B, Ravanat C, Cazenave JP. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischaemic cardiovascular diseases. J Thromb Haemost 2005; 03: 85-92.
9 Halbrugge M, Friedrich C, Eigenthaler M. et al. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP-and cAMP-elevating vasodilators. J Biol Chem 1990; 265: 3088-93.
10 Oury C, Toth-Zasamboki E, Vermylen J. et al. The platelet ATP and ADP receptors. Curr Pharm Des 2006; 12: 859-75.
11 Ingall AH, Dixon J, Bailey A. et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-20.
12 Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist ARC69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-7.
13 Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407-13.
14 Savi P, Labouret C, Delesque N. et al. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-83.
15 Kunapuli SP, Ding Z, Dorsam RT. et al. ADP receptors: targets for developing antithrombotic agents. Curr Pharm Des 2003; 09: 2303-16.
16 Danielewski O, Schultess J, Smolenski A. The NO/ cGMP pathway inhibits Rap1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost 2005; 93: 319-25.
17 Russo I, Doronzo G, Mattiello L. et al. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res 2004; 114: 265-73.
18 Jacobsson F, Swahn E, Wallentin L. et al. Safety profile and tolerability of intravenous AR-C69931MX a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002; 24: 752-65.
19 Hezard N, Metz D, Garnotel R. et al. Platelet VASP phosphorylation assessment in clopidogrel-treated patients: lack of agreement between Western blot and flow cytometry. Platelets 2005; 16: 474-81.
20 Barragan P, Bouvie JL, Roquebert PO. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of Vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
21 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Circulation 2003; 107: 2908-13.
22 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.